A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as
determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and
to describe the safety profile of darbepoetin alfa in patients with MDS. The secondary
objective is to assess bone marrow progenitor BFU-E growth before and after treatment with
darbepoetin alfa.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.